{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    50,
    51,
    57,
    62,
    63,
    70
  ],
  "modelUsed": "gemini-2.5-pro",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "Administration of study treatment, which is defined as Time = 0 min",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Once bedside PG reaches <60 mg/dL, the insulin infusion is stopped and approximately 5 minutes later study drug is administered.  Indicates Time = 0 min."
      },
      {
        "id": "anchor_1",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Screening\nPeriod"
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_3",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_interval_5",
        "type": "Interval",
        "interval": "PT15M",
        "minObservations": 5,
        "sourceText": "Predose, 15, 30, \n60, 120, 240 min"
      },
      {
        "id": "rep_interval_9",
        "type": "Interval",
        "interval": "PT5M",
        "minObservations": 12,
        "sourceText": "Predose, 5, 10, 15, \n20, 25, 30, 40, 50, \n60, 90, 120, 240 \nmin"
      },
      {
        "id": "rep_interval_13",
        "type": "Interval",
        "interval": "PT15M",
        "minObservations": 4,
        "sourceText": "Predose, 15, 30, \n60, 120 min"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "P28D",
        "endOffset": "P2D",
        "sourceText": "Days -28\nto -2"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "Screening\nPeriod"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "washout \nperiod"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "2 days \nafter"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "6 hours after"
      },
      {
        "id": "rep_window_24",
        "type": "Continuous",
        "sourceText": "4 hours after"
      }
    ],
    "samplingConstraints": [
      {
        "id": "sampling_1",
        "activityId": "PK_PD_Sampling_Period_1_2",
        "minPerWindow": 6,
        "windowDuration": "PT4H",
        "timepoints": [
          "predose",
          "15min",
          "30min",
          "60min",
          "120min",
          "240min"
        ]
      },
      {
        "id": "sampling_2",
        "activityId": "Immunogenicity_Followup",
        "minPerWindow": 1,
        "windowDuration": "P12W",
        "timepoints": [
          "every 12 weeks"
        ]
      },
      {
        "id": "sampling_3",
        "activityId": "PK_Followup",
        "minPerWindow": 1,
        "windowDuration": "P12W",
        "timepoints": [
          "every 12 weeks"
        ]
      }
    ],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "WASHOUT",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "crossover study"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_4",
          "epoch_5",
          "epoch_6"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "Treatment Admission Visit",
          "Screening",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'Insufficient response to glucagon administration', 'path': ['RESCUE_PROCEDURES']}, {'condition': 'Subject meets criteria for discontinuation from the study', 'path': ['EARLY_TERMINATION', 'FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 8; SINGLE signals: 4"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Window",
        "rationale": "WINDOW signals: 3; EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "rationale": "WINDOW signals: 1; EPISODE signals: 2; SINGLE signals: 2; RECURRING signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 5; SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant\nMedications",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 4"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Window",
        "rationale": "WINDOW signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Glucose Measurement",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Insulin Infusion",
        "executionType": "Single",
        "rationale": "WINDOW signals: 3; SINGLE signals: 6"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 10; SINGLE signals: 1"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Inclusion Criteria Assessment",
        "executionType": "Single",
        "rationale": "Based on the Table of Contents, inclusion criteria are assessed once at the beginning of the study to determine eligibility."
      },
      {
        "activityId": "Exclusion Criteria Assessment",
        "executionType": "Single",
        "rationale": "Based on the Table of Contents, exclusion criteria are assessed once at the beginning of the study to determine eligibility."
      },
      {
        "activityId": "Treatment Assignment",
        "executionType": "Single",
        "rationale": "Based on the Table of Contents section 'Method of Treatment Assignment', this is a one-time event where a participant is assigned to a treatment group."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutDuration": "3 to 14 days",
      "washoutRequired": true,
      "carryoverPrevention": "Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days.",
      "sourceText": "crossover study"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "frequency_daily",
        "text": "multiple daily injection of long-acting insulin analog",
        "footnoteId": "[A]",
        "structuredCondition": "frequency.multiple_daily(injection.long_acting_insulin_analog)",
        "appliesToActivityIds": [
          "long-acting insulin analog injection"
        ],
        "sourceText": "multiple daily injection of long-acting insulin analog"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "women of childbearing potential participating must test negative for \npregnancy prior to initiation of treatment as indicated by a negative serum \npregnancy test at the screening visit followed by a negative urine \npregnancy test within",
        "footnoteId": "[A]",
        "structuredCondition": "eligibility.requires(population.wocbp, test.pregnancy.negative_before_treatment) AND sequence(test.pregnancy.serum@screening, test.pregnancy.urine)",
        "appliesToActivityIds": [
          "serum pregnancy test",
          "urine pregnancy test",
          "treatment initiation"
        ],
        "sourceText": "women of childbearing potential participating must test negative for \npregnancy prior to initiation "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "either one highly effective method of contraception or a combination \nof",
        "footnoteId": "[B]",
        "structuredCondition": "eligibility.requires(contraception.highly_effective OR contraception.combination)",
        "appliesToActivityIds": [
          "Contraception Assessment"
        ],
        "sourceText": "either one highly effective method of contraception or a combination \nof"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "postmenopausal, defined as either:",
        "footnoteId": "[B]",
        "structuredCondition": "eligibility.definition(population.postmenopausal)",
        "appliesToActivityIds": [
          "Eligibility Assessment"
        ],
        "sourceText": "postmenopausal, defined as either:"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "cessation of menses for at least",
        "footnoteId": "[a]",
        "structuredCondition": "eligibility.criteria(population.postmenopausal, condition.menses_cessation)",
        "appliesToActivityIds": [
          "Eligibility Assessment"
        ],
        "sourceText": "cessation of menses for at least"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "if warranted and agreed upon between both the investigator and sponsor",
        "footnoteId": "(s)",
        "structuredCondition": "condition.if_agreed(investigator, sponsor)",
        "sourceText": "if warranted and agreed upon between both the investigator and sponsor"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "Predose time point will be\nbetween insulin infusion \nstop and study treatment",
        "footnoteId": "L.",
        "structuredCondition": "timing.between(timepoint.predose, event.insulin_infusion_stop, event.study_treatment_start)",
        "appliesToActivityIds": [
          "Predose assessments"
        ],
        "sourceText": "Predose time point will be\nbetween insulin infusion \nstop and study treatment"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "a\nSamples for immunogenicity, should be collected every",
        "footnoteId": "s.",
        "structuredCondition": "frequency.periodic(collection.sample.immunogenicity)",
        "appliesToActivityIds": [
          "Immunogenicity Sample Collection"
        ],
        "sourceText": "a\nSamples for immunogenicity, should be collected every"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_after",
        "text": "Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, vital signs, and venipuncture",
        "footnoteId": "r.",
        "structuredCondition": "sequence(ECG, vital_signs, venipuncture)",
        "appliesToActivityIds": [
          "ECG",
          "vital signs",
          "venipuncture"
        ],
        "sourceText": "Note:  if multiple procedures take place at the same time point, the following order of the procedur"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "The nature of any conditions present at the time of the physical examination and any preexisting \nconditions will be documented",
        "footnoteId": "G.",
        "structuredCondition": "documentation.required(physical_examination.conditions, preexisting_conditions)",
        "appliesToActivityIds": [
          "Physical Examination"
        ],
        "sourceText": "The nature of any conditions present at the time of the physical examination and any preexisting \nco"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "Patients who are not enrolled within",
        "footnoteId": "t.",
        "sourceText": "Patients who are not enrolled within"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \nprotocol waivers or exemptions, are not permitted",
        "footnoteId": "y.",
        "sourceText": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \np"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "The patient may \nchoose to use a double barrier method of contraception",
        "footnoteId": "d.",
        "sourceText": "The patient may \nchoose to use a double barrier method of contraception"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "Thus, each barrier method must include use of a \nspermicide",
        "footnoteId": "d.",
        "sourceText": "Thus, each barrier method must include use of a \nspermicide"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \nwill be destroyed within",
        "footnoteId": "y.",
        "sourceText": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \n"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "procedure_conditional",
        "text": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, regulations, or \nlaboratory certification standards",
        "footnoteId": "s.",
        "sourceText": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, "
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_after",
        "text": "Blood pressure and pulse rate should be measured after at least",
        "footnoteId": "d.",
        "sourceText": "Blood pressure and pulse rate should be measured after at least"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "general",
        "text": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \nposture-induced symptoms",
        "footnoteId": "e.",
        "sourceText": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \n"
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "If the patient feels unable to stand, supine \nvital signs only will be recorded",
        "footnoteId": "s.",
        "sourceText": "If the patient feels unable to stand, supine \nvital signs only will be recorded"
      },
      {
        "id": "fn_cond_20",
        "conditionType": "general",
        "text": "Single ECGs will be collected and stored locally at the investigator’s site",
        "footnoteId": "F.",
        "sourceText": "Single ECGs will be collected and stored locally at the investigator’s site"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "general",
        "text": "The central ECG laboratory will perform a basic quality control check",
        "footnoteId": "y.",
        "sourceText": "The central ECG laboratory will perform a basic quality control check"
      },
      {
        "id": "fn_cond_22",
        "conditionType": "general",
        "text": "At a future time, the stored \nECG data may be overread at the central ECG laboratory for further evaluation of machine-read \nmeasurements or to meet regulatory requirements",
        "footnoteId": "e.",
        "sourceText": "At a future time, the stored \nECG data may be overread at the central ECG laboratory for further eva"
      },
      {
        "id": "fn_cond_23",
        "conditionType": "general",
        "text": "Concentrations of glucagon will be assayed using a validated liquid chromatography with \ntandem mass spectrometry method",
        "footnoteId": "r.",
        "sourceText": "Concentrations of glucagon will be assayed using a validated liquid chromatography with \ntandem mass"
      },
      {
        "id": "fn_cond_24",
        "conditionType": "general",
        "text": "The samples will be stored for up to a maximum of",
        "footnoteId": "s.",
        "sourceText": "The samples will be stored for up to a maximum of"
      },
      {
        "id": "fn_cond_25",
        "conditionType": "general",
        "text": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time points to determine \nthe concentrations of glucagon",
        "footnoteId": "n.",
        "sourceText": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time"
      },
      {
        "id": "fn_cond_26",
        "conditionType": "general",
        "text": "A PK sample may be collected at these \nsame time points",
        "footnoteId": "t.",
        "sourceText": "A PK sample may be collected at these \nsame time points"
      },
      {
        "id": "fn_cond_27",
        "conditionType": "general",
        "text": "Treatment-emergent antidrug antibodies",
        "footnoteId": "r.",
        "sourceText": "Treatment-emergent antidrug antibodies"
      },
      {
        "id": "fn_cond_28",
        "conditionType": "general",
        "text": "A PK \nsample may be collected at the follow-up immunogenicity assessment",
        "footnoteId": "t.",
        "sourceText": "A PK \nsample may be collected at the follow-up immunogenicity assessment"
      },
      {
        "id": "fn_cond_29",
        "conditionType": "general",
        "text": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; however, if patients are unwilling or \nunable to return for the visit, this is not considered a protocol violation",
        "footnoteId": "r.",
        "sourceText": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; howev"
      },
      {
        "id": "fn_cond_30",
        "conditionType": "general",
        "text": "male patients: agree to use an effective method of contraception for the \nduration of the study and for",
        "footnoteId": "[2]",
        "sourceText": "male patients: agree to use an effective method of contraception for the \nduration of the study and "
      },
      {
        "id": "fn_cond_31",
        "conditionType": "general",
        "text": "female patients:",
        "footnoteId": "[3]",
        "sourceText": "female patients:"
      },
      {
        "id": "fn_cond_32",
        "conditionType": "general",
        "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
        "footnoteId": "6.",
        "sourceText": "Study Population\nEligibility of patients for the study will be based on the results of screening med"
      },
      {
        "id": "fn_cond_33",
        "conditionType": "timing_after",
        "text": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \nscreening and/or enrollment:",
        "footnoteId": "1.",
        "sourceText": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the fol"
      },
      {
        "id": "fn_cond_34",
        "conditionType": "general",
        "text": "Study Assessments and Procedures\nSection",
        "footnoteId": "9.",
        "sourceText": "Study Assessments and Procedures\nSection"
      },
      {
        "id": "fn_cond_35",
        "conditionType": "general",
        "text": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section",
        "footnoteId": "1.",
        "sourceText": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section"
      },
      {
        "id": "fn_cond_36",
        "conditionType": "general",
        "text": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \nas either an increase in PG to >",
        "footnoteId": "1.",
        "sourceText": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving tr"
      },
      {
        "id": "fn_cond_37",
        "conditionType": "general",
        "text": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynamic",
        "footnoteId": "2.",
        "sourceText": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynam"
      },
      {
        "id": "fn_cond_38",
        "conditionType": "general",
        "text": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool",
        "footnoteId": "3.",
        "sourceText": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-repo"
      },
      {
        "id": "fn_cond_39",
        "conditionType": "general",
        "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
        "footnoteId": "1.",
        "sourceText": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bed"
      },
      {
        "id": "fn_cond_40",
        "conditionType": "general",
        "text": "Treatment of Overdose\nFor the purposes of this study, an overdose of LY",
        "footnoteId": "4.",
        "sourceText": "Treatment of Overdose\nFor the purposes of this study, an overdose of LY"
      },
      {
        "id": "fn_cond_41",
        "conditionType": "general",
        "text": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix",
        "footnoteId": "1.",
        "sourceText": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix"
      },
      {
        "id": "fn_cond_42",
        "conditionType": "general",
        "text": "Vital Signs\nFor each patient, vital sign measurements should be conducted according to the Schedule of \nActivities",
        "footnoteId": "2.",
        "sourceText": "Vital Signs\nFor each patient, vital sign measurements should be conducted according to the Schedule "
      },
      {
        "id": "fn_cond_43",
        "conditionType": "general",
        "text": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \nActivities",
        "footnoteId": "3.",
        "sourceText": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the"
      },
      {
        "id": "fn_cond_44",
        "conditionType": "general",
        "text": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facility \ndesignated by the sponsor",
        "footnoteId": "1.",
        "sourceText": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facilit"
      },
      {
        "id": "fn_cond_45",
        "conditionType": "general",
        "text": "Pharmacodynamics\nAt times specified in the Schedule of Activities",
        "footnoteId": "7.",
        "sourceText": "Pharmacodynamics\nAt times specified in the Schedule of Activities"
      },
      {
        "id": "fn_cond_46",
        "conditionType": "general",
        "text": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities",
        "footnoteId": "1.",
        "sourceText": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities"
      },
      {
        "id": "fn_cond_47",
        "conditionType": "general",
        "text": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \nback to the site for follow-up immunogenicity assessment",
        "footnoteId": "6.",
        "sourceText": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \nde"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Treatment Success for Hypoglycemia Recovery",
        "endpointType": "Primary",
        "inputs": [
          "PG",
          "glucagon_admin_time",
          "PG_nadir"
        ],
        "timeWindow": {
          "reference": "glucagon administration",
          "duration": "PT30M"
        },
        "algorithm": "(PG_at_t >= 70) OR (PG_at_t - PG_nadir >= 20), where t is within 30 minutes of glucagon administration. PG_nadir is the minimum PG at the time of or within 10 minutes following glucagon administration.",
        "successCriteria": "A patient achieves treatment success if, within 30 minutes of glucagon administration, their Plasma Glucose (PG) is ≥70 mg/dL OR their PG has increased by ≥20 mg/dL from nadir.",
        "sourceText": "Treatment success is defined as either an increase in PG to ≥70 mg/dL or an increase of ≥20 mg/dL from PG nadir within 30 minutes after receiving study treatment. The nadir is defined as the minimum P"
      },
      {
        "id": "ep_2",
        "name": "Change from Baseline in Plasma Glucose",
        "endpointType": "Secondary",
        "inputs": [
          "PG_baseline",
          "PG_post_baseline"
        ],
        "timeWindow": {
          "reference": "Not specified",
          "duration": "Not specified"
        },
        "algorithm": "PG_post_baseline - PG_baseline",
        "successCriteria": "Not specified in the provided text.",
        "sourceText": "Secondary efficacy measures will be determined from the pharmacodynamic (PD) characterization of PG profiles, including evaluation of change from baseline PG concentrations."
      },
      {
        "id": "ep_3",
        "name": "Assessment of Subjective Hypoglycemia Symptoms",
        "endpointType": "Exploratory",
        "inputs": [
          "Edinburgh Hypoglycemia Scale score"
        ],
        "timeWindow": {
          "reference": "Multiple time points including initiation of hypoglycemia induction and post-glucagon administration",
          "duration": "Not specified"
        },
        "algorithm": "Assessment via survey tool. Specific calculation (e.g., change from baseline) is not defined.",
        "successCriteria": "Not specified in the provided text.",
        "sourceText": "Subjective hypoglycemia symptoms will be assessed using a self-reported assessment tool (Edinburgh Hypoglycemia Scale; Appendix 7) during the initiation of the hypoglycemia induction, as well as at va"
      },
      {
        "id": "ep_4",
        "name": "Assessment of Hypoglycemia Awareness",
        "endpointType": "Exploratory",
        "inputs": [
          "Clarke Hypoglycemia Awareness Survey score"
        ],
        "timeWindow": {
          "reference": "Period 1 Day -1",
          "duration": "Single time point"
        },
        "algorithm": "Assessment via survey tool. Specific calculation is not defined.",
        "successCriteria": "Not specified in the provided text.",
        "sourceText": "The ability of the patient to identify hypoglycemic symptoms and describe their frequency will be captured at Period 1 Day -1 (see Schedule of Activities; Section 2). This self-report assessment will "
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Treatment Success",
        "variableType": "Categorical",
        "sourceVariables": [
          "Plasma Glucose (PG)"
        ],
        "derivationRule": "A binary variable indicating treatment success, defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir PG, assessed at any time point within 30 minutes after administration of glucagon.",
        "baselineDefinition": "The baseline for the change calculation component is the PG nadir, defined as the lowest PG value reached during the insulin-induced hypoglycemia phase prior to glucagon administration.",
        "baselineVisit": "Predose (Time 0)",
        "analysisWindow": "Within 30 minutes after administration of glucagon",
        "unit": "Categorical (Success/Failure)"
      },
      {
        "id": "dv_2",
        "name": "Change from Baseline in Plasma Glucose",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Plasma Glucose (PG)"
        ],
        "derivationRule": "PG value at a given post-dose time point - PG value at baseline.",
        "baselineDefinition": "The PG value at the time of glucagon administration (Time 0), which corresponds to the PG nadir.",
        "baselineVisit": "Predose (Time 0)",
        "analysisWindow": "Post-dose time points including 15, 30, 60, and 120 minutes.",
        "unit": "mg/dL"
      },
      {
        "id": "dv_3",
        "name": "Probable symptomatic hypoglycemia",
        "variableType": "Categorical",
        "sourceVariables": [
          "Hypoglycemia symptoms",
          "Plasma Glucose (PG)"
        ],
        "derivationRule": "An event is classified as 'Probable symptomatic hypoglycemia' if symptoms of hypoglycemia were present, but a PG measurement was not reported.",
        "analysisWindow": "Entire study period",
        "unit": "Categorical (Yes/No)"
      },
      {
        "id": "dv_4",
        "name": "Overall (or total) hypoglycemia",
        "variableType": "Composite",
        "sourceVariables": [
          "Documented hypoglycemia",
          "Probable symptomatic hypoglycemia",
          "Severe hypoglycemia"
        ],
        "derivationRule": "Combines cases of documented hypoglycemia and probable symptomatic hypoglycemia, including severe hypoglycemia. Relative hypoglycemia is excluded. Each event is counted only once in this category.",
        "analysisWindow": "Entire study period",
        "unit": "Categorical (Yes/No)"
      },
      {
        "id": "dv_5",
        "name": "Elevated Alanine Aminotransferase (ALT)",
        "variableType": "Categorical",
        "sourceVariables": [
          "Alanine Aminotransferase (ALT)",
          "ALT Upper Limit of Normal (ULN)"
        ],
        "derivationRule": "ALT value is ≥ 3 times the Upper Limit of Normal (ULN).",
        "analysisWindow": "Entire study period",
        "unit": "Categorical (Yes/No)"
      },
      {
        "id": "dv_6",
        "name": "Elevated Alkaline Phosphatase (ALP)",
        "variableType": "Categorical",
        "sourceVariables": [
          "Alkaline Phosphatase (ALP)",
          "ALP Upper Limit of Normal (ULN)"
        ],
        "derivationRule": "ALP value is ≥ 2 times the Upper Limit of Normal (ULN).",
        "analysisWindow": "Entire study period",
        "unit": "Categorical (Yes/No)"
      },
      {
        "id": "dv_7",
        "name": "Elevated Total Bilirubin (TBL)",
        "variableType": "Categorical",
        "sourceVariables": [
          "Total Bilirubin (TBL)",
          "TBL Upper Limit of Normal (ULN)"
        ],
        "derivationRule": "TBL value is ≥ 2 times the Upper Limit of Normal (ULN).",
        "analysisWindow": "Entire study period",
        "unit": "Categorical (Yes/No)"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Completed",
        "Discontinued",
        "Withdrawn",
        "Death",
        "LostToFollowUp"
      ],
      "states": [
        "OnTreatment",
        "Discontinued",
        "Withdrawn",
        "Death"
      ],
      "transitions": [
        {
          "fromState": "OnTreatment",
          "toState": "Discontinued",
          "trigger": "Discontinuation from treatment"
        },
        {
          "fromState": "OnTreatment",
          "toState": "OnTreatment",
          "trigger": "Enter washout period",
          "guardCondition": "period_complete AND NOT last_period"
        }
      ]
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "LY900018 with",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "tration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration. Secondary  To compare the safety and tolerability of 3 mg LY90"
      },
      {
        "id": "dosing_2",
        "treatmentName": "LY900018 and",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "adults with T1DM and T2DM: Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study (Study I8R-MC-B002 [B002]). Studies IGBC and IGBA demonstrated comparable safety and efficacy between 3 mg LY90"
      },
      {
        "id": "dosing_3",
        "treatmentName": "LY900018 or",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 60.0,
            "unit": "mg"
          }
        ],
        "sourceText": "be conducted to monitor bedside PG for safety. The insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately 5 minutes later patients will be administered either 3 mg LY90"
      },
      {
        "id": "dosing_4",
        "treatmentName": "Dosage Levels",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "g glucagon administered IM (comparator). Table IGBJ.2 shows the study treatment information. Table IGBJ.2. Study Treatments Treatment Name LY900018 GlucaGen Dosage Formulation Dry powder Dry powder Do"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Insulin",
        "frequency": "QD",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 2.0,
            "unit": "mU/kg/min",
            "description": "starting infusion rate"
          },
          {
            "amount": 4.0,
            "unit": "mU/kg/min",
            "description": "maximum infusion rate"
          }
        ],
        "durationDescription": "Until plasma glucose is <50 mg/dL",
        "titrationSchedule": "The infusion will be initiated at a rate of 2.0 mU/kg/min and may be increased every 15 minutes to a maximum of 4.0 mU/kg/min until the plasma glucose is <50 mg/dL."
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Nasal Glucagon (LY900018)",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "Single administration",
        "doseModifications": [
          "If the patient’s plasma glucose (PG) does not increase to ≥70 mg/dL or by ≥20 mg/dL from the nadir PG within 15 minutes of glucagon administration, a second dose of the same glucagon will be administered.",
          "If the patient’s PG does not increase to ≥70 mg/dL or by ≥20 mg/dL from the nadir PG within 15 minutes of the second glucagon administration, IV glucose will be administered."
        ]
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Intramuscular Glucagon",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "Single administration",
        "doseModifications": [
          "If the patient’s plasma glucose (PG) does not increase to ≥70 mg/dL or by ≥20 mg/dL from the nadir PG within 15 minutes of glucagon administration, a second dose of the same glucagon will be administered.",
          "If the patient’s PG does not increase to ≥70 mg/dL or by ≥20 mg/dL from the nadir PG within 15 minutes of the second glucagon administration, IV glucose will be administered."
        ]
      },
      {
        "id": "dosing_llm_4",
        "treatmentName": "IV glucose",
        "frequency": "PRN",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "As needed for rescue",
        "doseModifications": [
          "Administered if the patient’s plasma glucose (PG) does not increase to ≥70 mg/dL or by ≥20 mg/dL from the nadir PG within 15 minutes of the second glucagon administration."
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_1",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 28,
        "windowAfter": 28,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "Patients will undergo a screening examination within 28 days prior to enrollment. Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14"
      },
      {
        "id": "visit_llm_2",
        "visitName": "Period 1 - Day -1",
        "targetDay": -1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Treatment"
      },
      {
        "id": "visit_7",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "Samples for immunogenicity, should be collected every 12 weeks (84±7 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of the baseline titer) or until 1 year af"
      },
      {
        "id": "visit_2",
        "visitName": "Early Termination",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Treatment",
        "sourceText": "single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days. Patients will return for a follow-up visit 26 to 30 days after the last study treatment. Number of Patients"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Period 2 - Day -1",
        "targetDay": 8,
        "windowBefore": 5,
        "windowAfter": 6,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Period 2 - Day 1",
        "targetDay": 9,
        "windowBefore": 5,
        "windowAfter": 6,
        "isRequired": true,
        "visitNumber": 5,
        "epoch": "Treatment"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "a follow-up visit 26 to 30 days after the last study treatment. Number of Patients: Seventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "dynamic randomization",
      "centralRandomization": true,
      "sourceText": "I8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 23\nLY900018\n5. Study Design\n5.1.\nOverall Design\nThis is a Phase 3, multicenter, randomized, open-label, active comparator, single-dose, 2-period, \n2-"
    }
  }
}